{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:58:39Z","timestamp":1784357919170,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Healthcare professionals are faced with the new challenges of preventing and managing drug-related problems (DRPs) with oral anticancer therapy (OAT): side-effects, drug\u2013drug interactions (DDIs), non-adherence, or medication errors. This study aims to assess the impact of ONCORAL, a real-life multidisciplinary care plan for cancer patients based on community and hospital follow-up, for the first OAT cycle.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective cohort study was conducted between October 1, 2021 and October 1, 2022 including all outpatients starting OAT treatment. During the first OAT cycle, the program consists of 6 weekly scheduled face-to-face or phone consultations to prevent and manage DRPs. Nurse and pharmacist interventions (NPIs) are realized to optimize treatments (primary outcomes). Secondary outcomes included the relative dose intensity (RDI) of the first cycle.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 562 NPIs were performed by the ONCORAL team: that is, 87.1% of the 209 patients included, for a mean of 3.1\u2005\u00b1\u20052.2 NPIs\/patient. NPIs-concerned DRPs detected by the nurse and pharmacist (346, 61.6%), symptoms and\/or adverse effects reported as PROs by the patient or family (138, 24.6%), or pathway issues (78, 13.9%). Seventy-three DDIs were detected and managed during medication review, in a quarter of patients (n\u2005=\u200554\/209), leading to the discontinuation of a daily concomitant medication in 30 cases. The mean RDI at the end of the first cycle, calculated for 209 patients, was 83.1\u2005\u00b1\u200523.9% (17.56-144.23).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In these ambulatory cancer patients, the interest in tailored monitoring of DRPs as a whole, including the prevention and management of drug interactions in addition to symptoms and adverse effects, is highlighted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae241","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T15:58:25Z","timestamp":1726329505000},"source":"Crossref","is-referenced-by-count":7,"title":["Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program"],"prefix":"10.1093","volume":"30","author":[{"given":"Claire","family":"Lattard","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Herledan","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]},{"name":"Universit\u00e9 Lyon 1, EA 3738, CICLY , Lyon, 69921 OULLINS Cedex ,\u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Reverdy","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 d\u2019Oncologie m\u00e9dicale , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Antherieu","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 d\u2019h\u00e9matologie , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Gaelle","family":"Caffin","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Cerfon","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Maire","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Rivat","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"France","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 d\u2019h\u00e9matologie , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-8857","authenticated-orcid":false,"given":"Benoit","family":"You","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Lyon 1, EA 3738, CICLY , Lyon, 69921 OULLINS Cedex ,\u00a0","place":["France"]},{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 d\u2019Oncologie m\u00e9dicale , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Lyon 1, EA 3738, CICLY , Lyon, 69921 OULLINS Cedex ,\u00a0","place":["France"]},{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 d\u2019Oncologie m\u00e9dicale , 69495 Pierre-B\u00e9nite ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-4231","authenticated-orcid":false,"given":"Florence","family":"Ranchon","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]},{"name":"Universit\u00e9 Lyon 1, EA 3738, CICLY , Lyon, 69921 OULLINS Cedex ,\u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-8092","authenticated-orcid":false,"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Unit\u00e9 de Pharmacie Clinique Oncologique , 69495 Pierre-B\u00e9nite ,","place":["France"]},{"name":"Universit\u00e9 Lyon 1, EA 3738, CICLY , Lyon, 69921 OULLINS Cedex ,\u00a0","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"2025030607381007500_CIT0001","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2025030607381007500_CIT0002","doi-asserted-by":"crossref","first-page":"e12463","DOI":"10.1111\/ecc.12463","article-title":"Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents","volume":"26","author":"Escudero-Vilaplana","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"2025030607381007500_CIT0003","doi-asserted-by":"crossref","first-page":"e13753","DOI":"10.1111\/ecc.13753","article-title":"Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis","volume":"31","author":"Zerbit","year":"2022","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"2025030607381007500_CIT0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ecc.12124","article-title":"Adherence to oral antineoplastic agents by cancer patients: definition and literature review","volume":"23","author":"Bassan","year":"2014","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"8","key":"2025030607381007500_CIT0005","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.3390\/ijerph18084266","article-title":"Medication Experience and adherence to oral chemotherapy: a qualitative study of patients\u2019 and health professionals\u2019 perspectives","volume":"18","author":"Talens","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"19","key":"2025030607381007500_CIT0006","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2025030607381007500_CIT0007","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.bulcan.2020.08.014","article-title":"Patients on oral anticancer drugs and coordinated pathway: CHIMORAL, feedback from care providers","volume":"107","author":"Maritaz","year":"2020","journal-title":"Bull Cancer"},{"issue":"7","key":"2025030607381007500_CIT0008","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s00520-020-05875-2","article-title":"Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists","volume":"29","author":"Urakawa","year":"2021","journal-title":"Support Care Cancer"},{"issue":"4","key":"2025030607381007500_CIT0009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13561820.2021.1929103","article-title":"Evaluation of interprofessional care processes for patients treated with oral anticancer drugs","volume":"36","author":"Kinnaer","year":"2022","journal-title":"J Interprof Care"},{"issue":"9930","key":"2025030607381007500_CIT0010","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2025030607381007500_CIT0011","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"2025030607381007500_CIT0012","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00277-020-04045-y","article-title":"Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study","volume":"99","author":"Zerbit","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"2025030607381007500_CIT0013","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1186\/s12885-022-10346-4","article-title":"Patient reported outcomes based on EQ-5D-5L questionnaires in head and neck cancer patients: a real-world study","volume":"22","author":"Sprave","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"2025030607381007500_CIT0014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00432-021-03645-z","article-title":"Real-life drug\u2013drug and herb\u2013drug interactions in outpatients taking oral anticancer drugs: comparison with databases","volume":"148","author":"Prely","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2025030607381007500_CIT0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/cancers14030660","article-title":"Assessment of Patient Reported Outcomes (PROs) in outpatients taking oral anticancer drugs included in the real-life oncoral program","volume":"14","author":"Collomb","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"2025030607381007500_CIT0016","doi-asserted-by":"crossref","first-page":"e0243309","DOI":"10.1371\/journal.pone.0243309","article-title":"Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients\u2019 knowledge to manage adverse effects","volume":"15","author":"P\u00e9richou","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"2025030607381007500_CIT0017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11096-006-9027-5","article-title":"Validation of an instrument for the documentation of clinical pharmacists\u2019 interventions","volume":"28","author":"Allenet","year":"2006","journal-title":"Pharm World Sci"},{"issue":"18","key":"2025030607381007500_CIT0018","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.20.03088","article-title":"The Randomized AMBORA trial: impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents","volume":"39","author":"D\u00fcrr","year":"2021","journal-title":"J.\u00a0Clin.\u00a0Oncol"},{"issue":"1","key":"2025030607381007500_CIT0019","first-page":"13","article-title":"Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting","volume":"26","author":"Khrystolubova","year":"2020","journal-title":"J.\u00a0Clin.\u00a0Oncol"},{"issue":"8","key":"2025030607381007500_CIT0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12032-020-01393-7","article-title":"Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)","volume":"37","author":"Deluche","year":"2020","journal-title":"Med Oncol"},{"key":"2025030607381007500_CIT0021","doi-asserted-by":"crossref","first-page":"101780","DOI":"10.1016\/j.ejon.2020.101780","article-title":"Effects of a nurse-led medication self-management programme in women with oral treatments for metastatic breast cancer: a mixed-method randomised controlled trial","volume":"47","author":"Komatsu","year":"2020","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"2025030607381007500_CIT0022","doi-asserted-by":"crossref","first-page":"151140","DOI":"10.1016\/j.soncn.2021.151140","article-title":"The effect of educational follow-up with the motivational interview technique on self-efficacy and drug adherence in cancer patients using oral chemotherapy treatment: a randomized controlled trial","volume":"37","author":"G\u00f6nderen \u00c7akmak","year":"2021","journal-title":"Semin Oncol Nurs"},{"issue":"21","key":"2025030607381007500_CIT0023","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.3390\/jcm11216392","article-title":"Characteristics and cost of unscheduled hospitalizations in patients treated with new oral anticancer drugs in Germany: evidence from the randomized AMBORA trial","volume":"11","author":"D\u00fcrr","year":"2022","journal-title":"J Clin Med"},{"issue":"12","key":"2025030607381007500_CIT0024","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology: how common are they","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann.\u00a0Oncol"},{"issue":"3","key":"2025030607381007500_CIT0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.suponc.2011.09.005","article-title":"Implementing a standardized pharmacist assessment and evaluating the role of a pharmacist in a multidisciplinary supportive oncology clinic","volume":"10","author":"Mancini","year":"2012","journal-title":"J Support Oncol"},{"issue":"4","key":"2025030607381007500_CIT0026","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jgo.2015.05.001","article-title":"Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy","volume":"6","author":"Yeoh","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"2025030607381007500_CIT0027","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jgo.2018.02.001","article-title":"The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software","volume":"9","author":"Nightingale","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"2025030607381007500_CIT0028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cpt.2338","article-title":"Medication errors during treatment with new oral anticancer agents: consequences for clinical practice based on the AMBORA Study","volume":"110","author":"Schlichtig","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"2025030607381007500_CIT0029","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.3390\/jcm11154558","article-title":"New oral antitumor drugs and medication safety in uro-oncology: implications for clinical practice based on a subgroup analysis of the AMBORA trial","volume":"11","author":"Schlichtig","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"2025030607381007500_CIT0030","first-page":"1564","article-title":"Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center","volume":"25","author":"Solomon","year":"2019","journal-title":"J.\u00a0Oncol.\u00a0Pharm.\u00a0Pract"},{"issue":"6","key":"2025030607381007500_CIT0031","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11096-014-0029-4","article-title":"Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience","volume":"36","author":"Lopez-Martin","year":"2014","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"2025030607381007500_CIT0032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12032-019-1267-z","article-title":"Interaction between phytotherapy and oral anticancer agents: prospective study and literature review","volume":"36","author":"Clairet","year":"2019","journal-title":"Med Oncol"},{"key":"2025030607381007500_CIT0033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fphar.2012.00069","article-title":"An overview of the evidence and mechanisms of herb-drug interactions","volume":"3","author":"Fasinu","year":"2012","journal-title":"Front Pharmacol"},{"issue":"4","key":"2025030607381007500_CIT0034","doi-asserted-by":"crossref","first-page":"e0231828","DOI":"10.1371\/journal.pone.0231828","article-title":"Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Kirino","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"2025030607381007500_CIT0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11096-015-0235-8","article-title":"Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction","volume":"38","author":"Ribed","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"2025030607381007500_CIT0036","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/bjc.2011.47","article-title":"The use of herbal medicines by people with cancer: a cross-sectional survey","volume":"104","author":"Damery","year":"2011","journal-title":"Br J Cancer"},{"issue":"3","key":"2025030607381007500_CIT0037","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1534735411423920","article-title":"How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis","volume":"11","author":"Horneber","year":"2012","journal-title":"Integr Cancer Ther"},{"issue":"6","key":"2025030607381007500_CIT0038","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1055\/a-1487-6284","article-title":"Patterns and trends of herbal medicine use among patients with gynecologic cancer","volume":"81","author":"Theuser","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"6","key":"2025030607381007500_CIT0039","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/1078155215608523","article-title":"Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia","volume":"22","author":"Lam","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2025030607381007500_CIT0040","first-page":"951","article-title":"The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms","volume":"25","author":"Moulin","year":"2017","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"6","key":"2025030607381007500_CIT0041","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41591-022-01788-1","article-title":"Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial","volume":"28","author":"Mir","year":"2022","journal-title":"Nat Med"},{"key":"2025030607381007500_CIT0042","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-024-01702-1","article-title":"A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial","author":"Minvielle","year":"2024","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"10","key":"2025030607381007500_CIT0043","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ejca.2011.04.001","article-title":"One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients","volume":"47","author":"Kawashima","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"2025030607381007500_CIT0044","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cam4.302","article-title":"Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries","volume":"3","author":"Porta","year":"2014","journal-title":"Cancer Med"},{"issue":"1","key":"2025030607381007500_CIT0045","first-page":"371","article-title":"Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan","volume":"35","author":"Hirano","year":"2015","journal-title":"Anticancer Res"},{"issue":"6","key":"2025030607381007500_CIT0046","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"2025030607381007500_CIT0047","article-title":"Arr\u00eat\u00e9 du 29 juillet 2021 modifiant l\u2019arr\u00eat\u00e9 du 30 novembre 2020 relatif \u00e0 l\u2019exp\u00e9rimentation de suivi \u00e0 domicile des patients sous anticanc\u00e9reux oraux. Journal Officiel de la R\u00e9publique Fran\u00e7aise.\u00a0n\u00b0 0180, 2021","author":"MINISTERE DES SOLIDARITES ET DE LA SANTE"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae241\/59123219\/oyae241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae241\/59123219\/oyae241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T07:38:29Z","timestamp":1741246709000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae241\/7758104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae241","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,14]]},"article-number":"oyae241"}}